Clinical trial
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not…
NCT00295633 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00295633 |
|---|---|
| Title | A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone |
| Official title | A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin |
| Enrollment | 565 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | Feb 24, 2006 |
| Last update posted | Apr 7, 2015 |
| Countries | Argentina, Canada, India, Mexico, Peru, Philippines, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: